Attach to Form 990 or Form 990-EZ.
Go to
www.irs.gov/Form990 for instructions and the latest information.
| (i) Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 10 above (see instructions)) | (iv) Is the organization listed in your governing document? | (v) Amount of monetary support (see instructions) | (vi) Amount of other support (see instructions) | |
|---|---|---|---|---|---|---|
| Yes | No | |||||
|
Total |
||||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2019 | (b) 2020 | (c) 2021 | (d) 2022 | (e) 2023 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grant.") .. | 13,046,433 | 15,661,608 | 20,139,699 | 19,131,206 | 21,134,092 | 89,113,038 |
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf .... | ||||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | ||||||
| 4 | Total. Add lines 1 through 3 | 13,046,433 | 15,661,608 | 20,139,699 | 19,131,206 | 21,134,092 | 89,113,038 |
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f) .. | 468,521 | |||||
| 6 | Public support. Subtract line 5 from line 4. | 88,644,517 | |||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2019 | (b) 2020 | (c) 2021 | (d) 2022 | (e) 2023 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | 13,046,433 | 15,661,608 | 20,139,699 | 19,131,206 | 21,134,092 | 89,113,038 |
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | 2,417,283 | 3,252,026 | 1,704,321 | 1,599,807 | 2,265,272 | 11,238,709 |
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. | 219,523 | 8,150 | 160,156 | 47,396 | 435,225 | |
| 11 | Total support. Add lines 7 through 10 | 100,786,972 | |||||
Calendar year (or fiscal
year beginning in) ![]() |
(a) 2019 | (b) 2020 | (c) 2021 | (d) 2022 | (e) 2023 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | ||||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513 ..... | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge | ||||||
| 6 | Total. Add lines 1 through 5 | ||||||
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public support. (Subtract line 7c from line 6.) | ||||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2019 | (b) 2020 | (c) 2021 | (d) 2022 | (e) 2023 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | ||||||
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | ||||||
| 11 | Net income from unrelated business activities not included on line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .. | ||||||
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | ||||||
| Section A - Adjusted Net Income | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Net short-term capital gain | 1 | ||||
| 2 | Recoveries of prior-year distributions | 2 | ||||
| 3 | Other gross income (see instructions) | 3 | ||||
| 4 | Add lines 1 through 3 | 4 | ||||
| 5 | Depreciation and depletion | 5 | ||||
| 6 | Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) | 6 | ||||
| 7 | Other expenses (see instructions) | 7 | ||||
| 8 | Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) | 8 | ||||
| Section B - Minimum Asset Amount | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): | 1 | ||||
| a | Average monthly value of securities | 1a | ||||
| b | Average monthly cash balances | 1b | ||||
| c | Fair market value of other non-exempt-use assets | 1c | ||||
| d | Total (add lines 1a, 1b, and 1c) | 1d | ||||
| e |
Discount claimed for blockage or other factors (explain in detail in Part VI): |
|||||
| 2 | Acquisition indebtedness applicable to non-exempt use assets | 2 | ||||
| 3 | Subtract line 2 from line 1d | 3 | ||||
| 4 | Cash deemed held for exempt use. Enter 0.015 of line 3 (for greater amount, see instructions). | 4 | ||||
| 5 | Net value of non-exempt-use assets (subtract line 4 from line 3) | 5 | ||||
| 6 | Multiply line 5 by 0.035 | 6 | ||||
| 7 | Recoveries of prior-year distributions | 7 | ||||
| 8 | Minimum Asset Amount (add line 7 to line 6) | 8 | ||||
| Section C - Distributable Amount | Current Year | |||||
| 1 | Adjusted net income for prior year (from Section A, line 8, Column A) | 1 | ||||
| 2 | Enter 85% of line 1 | 2 | ||||
| 3 | Minimum asset amount for prior year (from Section B, line 8, Column A) | 3 | ||||
| 4 | Enter greater of line 2 or line 3 | 4 | ||||
| 5 | Income tax imposed in prior year | 5 | ||||
| 6 | Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) | 6 | ||||
| Section D - Distributions | Current Year | |
|---|---|---|
| 1 Amounts paid to supported organizations to accomplish exempt purposes | 1 | |
|
2
Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity |
2 | |
| 3 Administrative expenses paid to accomplish exempt purposes of supported organizations | 3 | |
| 4 Amounts paid to acquire exempt-use assets | 4 | |
| 5 Qualified set-aside amounts (prior IRS approval required - provide details in Part VI) | 5 | |
| 6 Other distributions (describe in Part VI). See instructions | 6 | |
| 7Total annual distributions. Add lines 1 through 6. | 7 | |
|
8
Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions |
8 | |
| 9 Distributable amount for 2023 from Section C, line 6 | 9 | |
| 10 Line 8 amount divided by Line 9 amount | 10 | |
| Section E - Distribution Allocations (see instructions) |
(i) Excess Distributions |
(ii) Underdistributions Pre-2023 |
(iii) Distributable Amount for 2023 |
|
|---|---|---|---|---|
| 1 Distributable amount for 2023 from Section C, line 6 | ||||
|
2
Underdistributions, if any, for years prior to 2023 (reasonable cause required-- explain in Part VI).
See instructions. |
||||
| 3 Excess distributions carryover, if any, to 2023: | ||||
| a From 2018....... | ||||
| b From 2019....... | ||||
| c From 2020....... | ||||
| d From 2021....... | ||||
| e From 2022....... | ||||
| fTotal of lines 3a through e | ||||
| g Applied to underdistributions of prior years | ||||
| h Applied to 2023 distributable amount | ||||
|
i
Carryover from 2018 not applied (see instructions) |
||||
| j Remainder. Subtract lines 3g, 3h, and 3i from line 3f. | ||||
| 4Distributions for 2023 from Section D, line 7: | ||||
| $ | ||||
| a Applied to underdistributions of prior years | ||||
| b Applied to 2023 distributable amount | ||||
| c Remainder. Subtract lines 4a and 4b from line 4. | ||||
|
5
Remaining underdistributions for years prior to 2023, if any. Subtract lines 3g and 4a from line 2. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
6
Remaining underdistributions for 2023. Subtract lines 3h and 4b from line 1. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
7 Excess distributions carryover to 2024. Add lines 3j and 4c. |
||||
| 8 Breakdown of line 7: | ||||
| a Excess from 2019..... | ||||
| b Excess from 2020..... | ||||
| c Excess from 2021..... | ||||
| d Excess from 2022..... | ||||
| e Excess from 2023..... | ||||
| Facts And Circumstances Test |
|---|
| Return Reference | Explanation |
|---|---|
| PART II, SECTION B, LINE 10: | OTHER INCOME REPRESENTS GROSS INCOME FROM FUNDRAISING EVENTS. |
| Software ID: | |
| Software Version: |
| Return Reference | Explanation |
|---|---|
| FORM 990, PART III, LINE 4A | RESEARCH PROGRAM $23,621,306 GRANTS $21,875,654 THE LUSTGARTEN FOUNDATION'S MISSION IS TO ADVANCE THE BEST SCIENCE TO TRANSFORM PANCREATIC CANCER INTO A CURABLE DISEASE. 2024 MARKED THE FOUNDATION'S 26TH YEAR OF DRIVING PIONEERING PANCREATIC CANCER RESEARCH BREAKTHROUGHS, ACCELERATING PROGRESS FASTER THAN EVER BEFORE AND PROVIDING A MORE HOPEFUL FUTURE FOR ALL PATIENTS. IN 2024, THE FOUNDATION AWARDED 10 NEW GRANTS TOTALING UP TO $10.3 MILLION TO RESEARCHERS AT SEVEN LEADING INSTITUTIONS. OF THE NEW GRANTS AWARDED, 30% SUPPORT DRUG DEVELOPMENT PROJECTS; 30% SUPPORT EARLY DETECTION AND INTERCEPTION EFFORTS; AND 40% SUPPORT PERSONALIZED MEDICINE STUDIES. WITH THE ADDITION OF THESE NEW GRANTS, THE FOUNDATION NOW SUPPORTS 62 ACTIVE GRANTS ACROSS 33 INSTITUTIONS. THE CUMULATIVE TOTAL THE LUSTGARTEN FOUNDATION INVESTED IN RESEARCH THROUGH JUNE 2024 IS $287.2 MILLION. DURING FY24, MAJOR LUSTGARTEN-FUNDED INITIATIVES INCLUDED: - THE LUSTGARTEN FOUNDATION-SWIM ACROSS AMERICA-AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) EARLY DETECTION RESEARCH GRANT WAS AWARDED TO RENATO OSTUNI, PHD, UNIVERSITA VITA-SALUTE, SAN RAFFAELE, ITLAY, FOR HIS STUDY, "TARGETING THE PGE2-IL-1B AXIS FOR PDAC DIAGNOSIS AND EARLY TREATMENT." - ELLIOT FISHMAN, MD, JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE, AND HIS TEAM ARE COLLABORATING WITH MICROSOFT AI FOR GOOD, TO BRING AUTOMATED TOOLS TO PANCREATIC CANCER DETECTION AND MANAGEMENT OF HIGH-RISK INDIVIDUALS. MICROSOFT RESEARCH HAS DEVELOPED AN EBM (EXPLAINABLE BOOSTING MACHINE), AND THE COLLABORATION HAS ENABLED THE JOHNS HOPKINS TEAM TO DEVELOP AND EVALUATE TWO AI MODELS FOR PATIENTS WITH PANCREATIC CYSTS, USING CLINICAL FEATURES ALONE OR COMBINED WITH THEIR CUSTOM-DESIGNED SOFTWARE. DR. FISHMAN AND HIS COLLEAGUES ARE ALSO COLLABORATING WITH THE MICROSOFT TEAM TO OPTIMIZE THE EARLY DETECTION OF SMALL PANCREATIC TUMORS MEASURING 2 CM OR LESS. DR. ALAN YUILLE'S STUDY AT JOHNS HOPKINS BUILDS ON THE SUCCESS OF THE FELIX PROGRAM, FUNDED BY LUSTGARTEN SINCE 2016. THE FELIX PROGRAM USES DATA FROM THOUSANDS OF CT SCANS TO TEACH COMPUTERS TO DETECT TUMORS SMALL ENOUGH TO BE MISSED BY EVEN THE MOST EXPERIENCED RADIOLOGISTS. ENTITLED "FELIX CIVITAS," THIS PROJECT INVOLVES RESEARCHERS WORKING TO ENSURE THE AI ALGORITHMS WILL ASSIST DOCTORS AND RADIOLOGISTS IN A WAY THAT ALIGNS BEST WITH THEIR NEEDS AND PRIORITIES. - THE LUSTGARTEN ADVANCING BREAKTHROUGH SCIENCE (LABS) PROGRAM, A HALLMARK OF THE FOUNDATION'S UNIQUE RESEARCH STRATEGY, HAD AN INCREDIBLY SUCCESSFUL YEAR ADVANCING RESEARCH AT ITS SIX DEDICATED LABORATORIES. SPECIFICALLY, THE LABS SITE AT DANA-FARBER CANCER INSTITUTE, LED BY BRIAN WOLPIN, MD, MPH, IS EVALUATING NOVEL SURVEILLANCE METHODS TO IMPROVE EARLY DETECTION RATES FOR THOSE WITH AN INCREASED RISK OF PANCREATIC CANCER BASED ON FAMILY HISTORY/INHERITED RISK. BUILDING ON HER PREVIOUS WORK DEVELOPING A VACCINE FOR MUTATED KRAS, ELIZABETH JAFFEE, MD, DIRECTOR OF ONE OF THE LABS SITES AT JOHNS HOPKINS AND LUSTGARTEN'S CHIEF MEDICAL ADVISOR, IS LEADING NEW RESEARCH DEMONSTRATING THAT T CELL RECEPTORS THAT ARE SPECIFIC FOR MUTATED KRAS AND ARE PRESENT ON PATIENTS, CAN BE CLONED INTO T CELLS AND USED IN ADOPTIVE THERAPIES. THIS RESEARCH IS SO IMPORTANT BECAUSE THE KRAS GENE IS MUTATED IN THE VAST MAJORITY OF PANCREATIC CANCER PATIENTS. THE LABS PROGRAM PROVIDES LONG-TERM FUNDING TO PROMOTE THE DEVELOPMENT OF INNOVATIVE IDEAS AND SPEED THE PACE OF DISCOVERY BY INCENTIVIZING INTERDISCIPLINARY TEAM SCIENCE, INCLUDING GROUPS WITH COMPLEMENTARY EXPERTISE ACROSS THE PIPELINE FROM TARGET DISCOVERY AND VALIDATION TO PRECLINICAL DEVELOPMENT AND CLINICAL TESTING. - THE ORGANOIDS FOR PERSONALIZED THERAPY PROGRAM WAS APPROVED FOR EXPANSION INTO THE FOURTH PHASE. LED BY DAVID TUVESON, MD, PHD AT COLD SPRING HARBOR LABORATORY, ORGANOID PERSONALIZED THERAPEUTICS PHASE 4 PROJECT-OPT4" BUILDS ON PREVIOUS PHASES AND SUCCESSES, TO LEVERAGE PATIENT-DERIVED ORGANOID MODELS FOR THE STUDY OF PANCREATIC CANCER AND WILL ADVANCE THE DEVELOPMENT OF EARLY DETECTION TOOLS AND THERAPEUTIC OPTIONS.OPT4 FOCUSES ON UTILIZING PATIENT DERIVED ORGANOIDS TO INVESTIGATE PANCREATIC CANCER INITIATION, CONDUCT DRUG SCREENS FOR CLINICALLY ACTIONABLE RESULTS, AND EVALUATE KRAS INHIBITORS AND COMBINATION THERAPIES AS POTENTIAL DRUG CANDIDATES FOR PANCREATIC CANCER. ADDITIONALLY, THE PASS-01 TRIAL, A LANDMARK STUDY FUNDED BY LUSTGARTEN IN COLLABORATION WITH STAND UP TO CANCER AND PANCREATIC CANCER CANADA, COMPLETED ENROLLMENT OF 146 METASTATIC PANCREATIC CANCER PATIENTS IN 2024 AND GENERATED THE MOST COMPREHENSIVE MOLECULAR ANALYSIS OF A COHORT OF THIS SIZE IN PANCREATIC CANCER. - THE LUSTGARTEN FOUNDATION-AACR CAREER DEVELOPMENT AWARDS HONORING RUTH BADER GINSBURG AND JOHN ROBERT LEWIS WERE GIVEN TO TRACY LIU, PHD, WEST VIRGINIA UNIVERSITY, FOR HER STUDY, "EXPANDING IMMUNOTHERAPY IN PANCREATIC CANCER BY TARGETING MYELOPEROXIDASE, AND CHRISTINA TOWERS, PHD, SALK INSTITUTE FOR BIOLOGICAL STUDIES, FOR HER STUDY, "TARGETING METABOLIC ADAPTATIONS TO AUTOPHAGY INHIBITION IN PDAC." THESE AWARDS FOSTER AND GROW THE NUMBER OF EARLY-CAREER WOMEN AND UNDERREPRESENTED SCIENTISTS WORKING IN PANCREATIC CANCER RESEARCH AND HONOR THE LIVES AND LEGACIES OF TWO ICONIC AMERICANS LOST TO PANCREATIC CANCER. THE AWARDS SUPPORT TRAILBLAZING INVESTIGATORS COMMITTED TO INCREASING THE UNDERSTANDING AND TREATMENT OF PANCREATIC CANCER. - THE LUSTGARTEN EQUITY, ACCESSIBILITY, AND DIVERSITY (LEAD) GRANT WAS PRESENTED TO FIYINFOLU BALOGUN, MD, PHD, MEMORIAL SLOAN KETTERING CANCER CENTER, FOR HIS STUDY, "INVESTIGATING THE MOLECULAR BASES OF PANCREATIC CANCER DISPARITIES IN UNDERSERVED MINORITY COMMUNITIES AND INCREASING CLINICAL TRIAL RECRUITMENT EMPLOYING LINGUISTIC INTERVENTION." THE LEAD GRANTS WERE CREATED TO INCREASE THE RECRUITMENT AND RETENTION OF UNDERREPRESENTED GROUPS IN PANCREATIC CANCER CLINICAL TRIALS. - THE INNOVATION AND COLLABORATION GRANT, WHICH PROVIDES SEED FUNDING FOR NOVEL RESEARCH PROJECTS WITH SIGNIFICANT POTENTIAL, WAS AWARDED TO LINDA RESAR, MD, JOHNS HOPKINS UNIVERSITY, FOR HER STUDY, "TARGETING HMGA1 TUMOR- STROMAL SIGNALING NETWORKS IN PANCREATIC CANCER." SHE IS INVESTIGATING THERAPIES BASED ON A PROTEIN CALLED HIGH MOBILITY GROUP A1 (HMGA1) INVOLVED IN REGULATING PATHWAYS THAT DRIVE TUMOR FORMATION AND PROGRESSION. - DR. ROBERT F. VIZZA LUSTGARTEN CLINICAL ACCELERATOR INITIATIVE (CAI) GRANTS WERE AWARDED TO KIM REISS BINDER, MD, HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA, FOR HER STUDY, "TESTING AND UNDERSTANDING ANTI-CTLA4 PLUS PARP INHIBITOR MAINTENANCE THERAPY IN PATIENTS WITH METASTATIC PANCREATIC CANCER WHO HAVE ACHIEVED STABLE DISEASE ON FOLFIRINOX;" ERIC CHRISTENSON, MD, JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE, FOR HIS STUDY, "A PILOT STUDY COMPARING NEOADJUVANT AND ADJUVANT GVAX VS A MUTATED KRAS PEPTIDE VACCINE GIVEN WITH ANTI-PD-1 AND ANTI-CD137 AGONIST FOR THE TREATMENT OF SURGICALLY RESECTABLE PANCREATIC ADENOCARCINOMA; AND ANDREW LOWY, MD, IN COLLABORATION WITH SHWETA JOSHI, PHD, BOTH FROM MOORES CANCER CENTER, UC SAN DIEGO, FOR THEIR STUDY, "SYK-TARGETED THERAPY WITH FOSTAMATINIB: A PROMISING AVENUE TO ENHANCE CHEMOTHERAPY RESPONSE IN PANCREATIC CANCER." --- THE CAI REDUCES THE TIME FROM CLINICAL TRIAL CONCEPT TO LAUNCH USING A LUSTGARTEN-DEVELOPED PROCESS BASED ON THE BEST AVAILABLE SCIENCE AND EMPLOYING INNOVATIVE BIOMARKERS. WITH THREE NEW TRIALS ADDED THIS YEAR, THERE ARE NOW 10 TRIALS SUPPORTED THROUGH THIS INNOVATIVE PROGRAM. --- TO MAXIMIZE THE VALUE OF THE CAI STUDIES, THE LUSTGARTEN FOUNDATION CONTINUED TO DEVELOP THE LUSTGARTEN UNITED CLINICAL INFORMATION DATABASE (LUCID) TO HOUSE THE CHARACTERISTICS OF PATIENTS ACROSS STUDIES AND LINK THEM TO PATIENT OUTCOMES. BY PROVIDING A CENTRALIZED PLATFORM FOR DATA SHARING AND ANALYSIS, LUCID PROMOTES COLLABORATION BETWEEN RESEARCHERS, LEADING TO FASTER RESEARCH ADVANCEMENTS. ADDITIONALLY, LUCID WILL HELP RESEARCHERS IDENTIFY NEW TREATMENT APPROACHES AND BIOMARKERS AND UNDERSTAND DISEASE HETEROGENEITY AND PATIENT SUBGROUPS, DETERMINING WAYS TO MATCH THE RIGHT PATIENTS TO THE RIGHT TREATMENTS AND IMPROVE OUTCOMES. - IN 2024, LUSTGARTEN CONTINUED OUR COLLABORATIONS WITH ORGANIZATIONS INCLUDING THE PANCREATIC CANCER COLLECTIVE, AMERICAN ASSOCIATION FOR CANCER RESEARCH, SWIM ACROSS AMERICA, CANCER RESEARCH INSTITUTE, AND BREAK THROUGH CANCER. THROUGH THESE PARTNERSHIPS, LUSTGARTEN BRINGS FOCUS AND STRATEGY TO PANCREATIC CANCER RESEARCH AND MAXIMIZES OUR COLLECTIVE FINANCIAL INVESTMENT SO WE CAN FUND THE MOST HIGH-RISK, HIGH-REWARD SCIENCE. |
| FORM 990, PART III, LINE 4B | PUBLIC EDUCATION AND INFORMATION PROGRAM $1,241,565 THE LUSTGARTEN FOUNDATION IS THE LARGEST PRIVATE FUNDER OF PANCREATIC CANCER RESEARCH IN THE WORLD, FUNDING PREEMINENT PANCREATIC CANCER RESEARCHERS, DRIVING THE PURSUIT OF BOLD AND INNOVATIVE SCIENCE TOWARD EARLIER DETECTION AND BETTER TREATMENTS, AND TRANSFORMING PANCREATIC CANCER INTO A CURABLE DISEASE. THE FOUNDATION FUNDS RESEARCH WHERE CREATIVE RISKS YIELD HIGH REWARDS TO ACCELERATE AND EXPAND LIFE-SAVING TREATMENT OPTIONS. WE BELIEVE TIME IS EVERYTHING TO PATIENTS AND THEIR FAMILIES, AND THAT COMMUNITY IS POWER. LUSTGARTEN PROGRAMS AND EVENTS PROVIDE PEOPLE AFFECTED BY PANCREATIC CANCER A VOICE AND A PLACE TO CREATE HOPE, TOGETHER. THE LUSTGARTEN FOUNDATION CREATED, PRINTED AND DISTRIBUTED MATERIALS TO UPDATE PATIENTS, CAREGIVERS, SURVIVORS, DONORS, VOLUNTEERS, WALK AND EVENT LEADERS AND CORPORATE SPONSORS ON RESEARCH DEVELOPMENTS, FOUNDATION MILESTONES, AND WALKS/EVENTS. MATERIALS INCLUDED: - LUSTGARTENLIVE! SERIES OF RESEARCH-FOCUSED, INTERACTIVE WEBINARS - PROGRESS & PROMISE NEWSLETTER - ANNUAL REPORT - IMPACT REPORT - RESEARCH MILESTONES UPDATE - MONTHLY E-NEWSLETTER WITH VIDEO INTRODUCTION - DIRECT MAIL AND ACQUISITION MAIL PIECES - MONTHLY PANCCHATS ON TWITTER, BRINGING EXPERTS AND PATIENTS TOGETHER TO DISCUSS TOPICS PERTINENT TO THE PANCREATIC CANCER COMMUNITY - INCREASED FOCUS ON VIDEO WE ALSO CONTINUED DISTRIBUTING OUR NAVIGATING PANCREATIC CANCER: A GUIDE FOR PATIENTS & CAREGIVERS HANDBOOK, CONTAINING INFORMATION ON MANAGING A PANCREATIC CANCER DIAGNOSIS AND TREATING THE DISEASE. THE BOOK AND MANY OF THE MATERIALS NOTED ABOVE ARE ACCESSIBLE AT WWW.LUSTGARTEN.ORG. |
| FORM 990, PART III, LINE 4C | PROFESSIONAL EDUCATION PROGRAM $757,498 PROFESSIONAL EDUCATION FOCUSED ON THE FOUNDATION'S SENIOR LEADERSHIP CONDUCTING HIGH-LEVEL MEETINGS WITH FUNDED SCIENTISTS AND DIRECTORS OF THE LABS PROGRAM SITES AND COLLABORATING ORGANIZATIONS, AS WELL AS ATTENDING/PRESENTING AT SCIENTIFIC MEETINGS FOR ORGANIZATIONS INCLUDING THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) AND STAND UP TO CANCER (SU2C). ADDITIONALLY, THE LUSTGARTEN FOUNDATION PROVIDED SUPPORT FOR AACR'S PANCREAS MEETING, EARLY DETECTION PLANNING WORKSHOP WITH THE MARK FOUNDATION, THE INTERNATIONAL WOMEN'S DAY SYMPOSIUM AT THE SALK INSTITUTE FOR BIOLOGICAL STUDIES, AND THE PANCREAS COURSE AT COLD SPRING HARBOR LABORATORY. |
| FORM 990, PART VI, SECTION A, LINE 2 | CHARLES F. DOLAN, JAMES L. DOLAN AND QUENTIN F. DOLAN - FAMILY AND BUSINESS RELATIONSHIP. MARCIA LUSTGARTEN, ANDREW LUSTGARTEN AND JESSICA LUSTGARTEN COURTEMANCHE - FAMILY RELATIONSHIP. JAMES L. DOLAN, PHILIP D'AMBROSIO, AND QUENTIN F. DOLAN - BUSINESS RELATIONSHIP. |
| FORM 990, PART VI, SECTION B, LINE 11B | FORM 990 IS REVIEWED BY THE CHIEF EXECUTIVE OFFICER FOR ACCURACY AND REASONABLENESS PRIOR TO SUBMISSION TO THE IRS. ADDITIONALLY, A COMPLETE COPY OF THE FINAL RETURN IS PROVIDED TO ALL VOTING BOARD MEMBERS PRIOR TO FILING WITH THE IRS. |
| FORM 990, PART VI, SECTION B, LINE 12C | THE ORGANIZATION HAS A WRITTEN CONFLICT OF INTEREST POLICY. THE WRITTEN POLICY REQUIRES ANNUAL DISCLOSURES BY ALL MEMBERS OF THE BOARD OF DIRECTORS, OFFICERS, AND KEY PERSONS OF ANY INTEREST THAT COULD GIVE RISE TO CONFLICT. THE ORGANIZATION REGULARLY AND CONSISTENTLY MONITORS AND ENFORCES THE COMPLIANCE OF THE CONFLICT OF INTEREST POLICY. IN THE INSTANCE WHERE A DIRECTOR HAS A CONFLICT, THEY ARE ASKED BY THE BOARD CHAIR TO RECUSE THEMSELVES FROM DELIBERATIONS, DECISIONS AND THE VOTE. |
| FORM 990, PART VI, SECTION B, LINE 15 | COMPENSATION FOR THE CHIEF EXECUTIVE OFFICER IS REVIEWED AND APPROVED ANNUALLY BY THE FINANCE COMMITTEE OF THE BOARD. TO SUPPORT THIS PROCESS, THE COMMITTEE UTILIZES A COMPENSATION SURVEY PROVIDED BY AN INDEPENDENT HUMAN RESOURCES CONSULTANT. THE MOST RECENT REVIEW OCCURRED IN MAY 2024. |
| FORM 990, PART VI, SECTION C, LINE 19 | AUDITED FINANCIAL STATEMENTS ARE MADE AVAILABLE ON THE ORGANIZATION'S WEBSITE. IN ADDITION, GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND AUDITED FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST. |
| FORM 990, PART XI, LINE 9: | LOSS ON LEASE TERMINATION -83,821. |
| Software ID: | |
| Software Version: |